Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer after a second trial failure dealt a major blow to the French healthcare company’s development prospects. The move weighed on shares and mounted pressure on Sanofi to bolster its pipeline of …
Read More »